349 related articles for article (PubMed ID: 17525906)
41. Co-operative study group for childhood acute lymphoblastic leukemia (COALL): long-term follow-up of trials 82, 85, 89 and 92.
Harms DO; Janka-Schaub GE
Leukemia; 2000 Dec; 14(12):2234-9. PubMed ID: 11187914
[TBL] [Abstract][Full Text] [Related]
42. Is cytarabine useful in the treatment of acute promyelocytic leukemia? Results of a randomized trial from the European Acute Promyelocytic Leukemia Group.
Adès L; Chevret S; Raffoux E; de Botton S; Guerci A; Pigneux A; Stoppa AM; Lamy T; Rigal-Huguet F; Vekhoff A; Meyer-Monard S; Maloisel F; Deconinck E; Ferrant A; Thomas X; Fegueux N; Chomienne C; Dombret H; Degos L; Fenaux P;
J Clin Oncol; 2006 Dec; 24(36):5703-10. PubMed ID: 17116939
[TBL] [Abstract][Full Text] [Related]
43. High-dose methotrexate in childhood all.
Moe PJ; Holen A
Pediatr Hematol Oncol; 2000 Dec; 17(8):615-22. PubMed ID: 11127393
[TBL] [Abstract][Full Text] [Related]
44. Phase I trial of high-dose tamoxifen as a modulator of drug resistance in combination with daunorubicin in patients with relapsed or refractory acute leukemia.
Berman E; McBride M; Lin S; Menedez-Botet C; Tong W
Leukemia; 1995 Oct; 9(10):1631-7. PubMed ID: 7564501
[TBL] [Abstract][Full Text] [Related]
45. Correlation between high vascular endothelial growth factor-A serum levels and treatment outcome in patients with standard-risk acute lymphoblastic leukemia: a report from Children's Oncology Group Study CCG-1962.
Avramis IA; Panosyan EH; Dorey F; Holcenberg JS; Avramis VI;
Clin Cancer Res; 2006 Dec; 12(23):6978-84. PubMed ID: 17145817
[TBL] [Abstract][Full Text] [Related]
46. Pharmacokinetics and metabolism of thiopurines in children with acute lymphoblastic leukemia receiving 6-thioguanine versus 6-mercaptopurine.
Erb N; Harms DO; Janka-Schaub G
Cancer Chemother Pharmacol; 1998; 42(4):266-72. PubMed ID: 9744770
[TBL] [Abstract][Full Text] [Related]
47. Comparison of the results of the treatment of adolescents and young adults with standard-risk acute lymphoblastic leukemia with the Programa Español de Tratamiento en Hematología pediatric-based protocol ALL-96.
Ribera JM; Oriol A; Sanz MA; Tormo M; Fernández-Abellán P; del Potro E; Abella E; Bueno J; Parody R; Bastida P; Grande C; Heras I; Bethencourt C; Feliu E; Ortega JJ
J Clin Oncol; 2008 Apr; 26(11):1843-9. PubMed ID: 18398150
[TBL] [Abstract][Full Text] [Related]
48. Therapeutic effectiveness of the ALL-XH-99 protocol for childhood acute lymphoblastic leukemia.
Wang YR; Jin RM; Xu JW; Xiao Y; Zhou DF; Zhang ZQ
Zhongguo Dang Dai Er Ke Za Zhi; 2008 Feb; 10(1):1-4. PubMed ID: 18289459
[TBL] [Abstract][Full Text] [Related]
49. Almost normal cognitive function in patients during therapy for childhood acute lymphoblastic leukemia without cranial irradiation according to ALL-BFM 95 and COALL 06-97 protocols: results of an Austrian-German multicenter longitudinal study and implications for follow-up.
Krappmann P; Paulides M; Stöhr W; Ittner E; Plattig B; Nickel P; Lackner H; Schrappe M; Janka G; Beck JD; Langer T
Pediatr Hematol Oncol; 2007 Mar; 24(2):101-9. PubMed ID: 17454775
[TBL] [Abstract][Full Text] [Related]
50. Liposomal daunorubicin versus standard daunorubicin: long term follow-up of the GIMEMA GSI 103 AMLE randomized trial in patients older than 60 years with acute myelogenous leukaemia.
Latagliata R; Breccia M; Fazi P; Iacobelli S; Martinelli G; Di Raimondo F; Sborgia M; Fabbiano F; Pirrotta MT; Zaccaria A; Amadori S; Caramatti C; Falzetti F; Candoni A; Mattei D; Morselli M; Alimena G; Vignetti M; Baccarani M; Mandelli F
Br J Haematol; 2008 Dec; 143(5):681-9. PubMed ID: 18950458
[TBL] [Abstract][Full Text] [Related]
51. Phase I study of liposomal daunorubicin in relapsed and refractory acute myeloid leukemia.
Bieker R; Lerchenmüller C; Wehmeyer J; Serve HL; Mesters RM; Büchner T; Berdel WE
Oncol Rep; 2003; 10(4):915-20. PubMed ID: 12792745
[TBL] [Abstract][Full Text] [Related]
52. Low-dose daunorubicin in induction treatment of childhood acute lymphoblastic leukemia: no long-term cardiac damage in a randomized study of the Dutch Childhood Leukemia Study Group.
Rammeloo LA; Postma A; Sobotka-Plojhar MA; Bink-Boelkens MT; Berg A; Veerman AJ; Kamps WA
Med Pediatr Oncol; 2000 Jul; 35(1):13-9. PubMed ID: 10881002
[TBL] [Abstract][Full Text] [Related]
53. [Acute lymphoblastic leukemia in childhood: the COALL studies].
Janka GE; Winkler K; Jürgens H; Göbel U; Gutjahr P; Spaar HJ
Klin Padiatr; 1986; 198(3):171-7. PubMed ID: 3523023
[TBL] [Abstract][Full Text] [Related]
54. [Study on elimination delay in high dose methotrexate therapy in childhood acute lymphoblastic leukemia].
Xu WQ; Tang YM; Fang CQ; Song H; Shi SW; Yang SL; Ren DT; Shen HQ; Qian BQ
Zhonghua Xue Ye Xue Za Zhi; 2005 Jan; 26(1):15-8. PubMed ID: 15946502
[TBL] [Abstract][Full Text] [Related]
55. Individualized toxicity-titrated 6-mercaptopurine increments during high-dose methotrexate consolidation treatment of lower risk childhood acute lymphoblastic leukaemia. A Nordic Society of Paediatric Haematology and Oncology (NOPHO) pilot study.
Frandsen TL; Abrahamsson J; Lausen B; Vettenranta K; Heyman M; Behrentz M; Castor A; Wehner PS; Frost BM; Andersen EW; Schmiegelow K
Br J Haematol; 2011 Oct; 155(2):244-7. PubMed ID: 21848519
[TBL] [Abstract][Full Text] [Related]
56. Prognostic significance of blasts in the cerebrospinal fluid without pleiocytosis or a traumatic lumbar puncture in children with acute lymphoblastic leukemia: experience of the Dutch Childhood Oncology Group.
; te Loo DM; Kamps WA; van der Does-van den Berg A; van Wering ER; de Graaf SS
J Clin Oncol; 2006 May; 24(15):2332-6. PubMed ID: 16710032
[TBL] [Abstract][Full Text] [Related]
57. Sequential continuous infusion of fludarabine and cytarabine associated with liposomal daunorubicin (DaunoXome) (FLAD) in primary refractory or relapsed adult acute myeloid leukemia patients.
Camera A; Rinaldi CR; Palmieri S; Cantore N; Mele G; Mettivier V; Miraglia E; Mastrullo L; Grimaldi F; Luciano L; Guerriero A; Rotoli B; Ferrara F
Ann Hematol; 2009 Feb; 88(2):151-8. PubMed ID: 18709502
[TBL] [Abstract][Full Text] [Related]
58. Randomized trial comparing liposomal daunorubicin with idarubicin as induction for pediatric acute myeloid leukemia: results from Study AML-BFM 2004.
Creutzig U; Zimmermann M; Bourquin JP; Dworzak MN; Fleischhack G; Graf N; Klingebiel T; Kremens B; Lehrnbecher T; von Neuhoff C; Ritter J; Sander A; Schrauder A; von Stackelberg A; Starý J; Reinhardt D
Blood; 2013 Jul; 122(1):37-43. PubMed ID: 23704089
[TBL] [Abstract][Full Text] [Related]
59. A comparison of the in vitro cytotoxicity of daunorubicin and liposomal daunorubicin in pediatric acute leukemia.
Goemans BF; Zwaan CM; Reinhardt D; Gibson BE; Hählen K; Kaspers GJ
Haematologica; 2006 Nov; 91(11):1573-4. PubMed ID: 17043024
[TBL] [Abstract][Full Text] [Related]
60. Higher plasma but not intracellular concentrations after infusion with liposomal daunorubicin compared with conventional daunorubicin in adult acute myeloid leukemia.
Löfgren C; Lehmann S; Jönsson-Videsäter K; Möllgård L; Linder O; Tidefelt U; Hassan M; Paul C
Ther Drug Monit; 2007 Oct; 29(5):626-31. PubMed ID: 17898654
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
